

Research Article

Diagnostic Accuracy of Immunologic Biomarkers for Accurate Diagnosis of Bloodstream Infection in Patients with Malignancy: Procalcitonin in Comparison with C-Reactive Protein

Mansoureh Shokripour ¹, Navid Omidifar ², Kouros Salami ¹,
Mohsen Moghadami ³ and Babak Samizadeh ¹

¹Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran

²Biotechnology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

³Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence should be addressed to Navid Omidifar; omidifar@gmail.com

Received 4 March 2020; Revised 2 August 2020; Accepted 21 October 2020; Published 31 October 2020

Academic Editor: Maria Lina Tornesello

Copyright © 2020 Mansoureh Shokripour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To calculate the diagnostic value of C-reactive protein (CRP) and serum procalcitonin (PCT) levels for the pathologic presence of microbes in the bloodstream of patients with malignancy, in comparison with blood culture. **Methodology.** Blood culture (by reference method) and assay results of PCT and CRP of febrile patients, with clinical suspicion to blood infections, were collected. Statistical aspects of PCT and CRP tests were evaluated. **Results.** Data from 255 cases were gathered. The area under the curve for differentiating bacteremia from nonbacteremia for PCT (0.741) was superior to that of CRP (0.612). Amongst the different cutoffs of PCT and CRP, the cutoff of ≥ 1.17 ng/ml and >47 mg/l had the sensitivity of 75 and 58.3%, the best NPV of 91.5% and 81.3%, and the best specificity of 79.9% and 72.8%, respectively. **Discussion.** Despite statistically nonsignificant results, PCT seems to be a superior indicator to CRP for rejecting the presence of microorganism in bloodstream. For PCT, the cutoff value of 1.17 ng/ml (bacteremia from nonbacteremia) had the highest NPV value of 91.5% in malignant patients, suspicion of sepsis.

1. Introduction

Infections are an important cause of morbidity and mortality amongst oncology patients, and neutropenia is recognized as the most important risk factor, which its severity and duration are associated with a higher rate of infection [1]. The classic symptoms of infection are fever and leukocytosis. Fever with a temperature greater than 38.3°C sublingually is alarming in cancer patients. Temperature greater than 38°C for more than an hour in a patient whose absolute neutrophil count (ANC) of peripheral blood is less than 500 cells per cubic millimeters or below is called neutropenia with fever. In these patients, since the immune system is suppressed by extensive chemical therapies, fever can be considered as the only positive finding as a probable infection that should be

further investigated [2]. Fever is a specific, but not a sensitive marker, and is influenced by noninfectious factors such as antipyretics. However, it is a criterion for sepsis [3, 4]. Also, leukocytosis has limitations in the diagnosis of infection and sepsis [5].

CRP is a well-known marker in the field of sepsis, and its association with the treatment of urosepsis was detected [6, 7]. Use of this marker to detect infectious diseases amongst children and adults is proven [8]. CRP measurement is an inexpensive test available in almost all healthcare centers, and some researchers prefer it over other markers [9].

Procalcitonin (PCT) was first introduced in 1993 by Assicot et al. as a sepsis-induced protein, found in the plasma of patients with infection and sepsis. Early studies

showed that this marker is mainly elevated in severe systemic inflammation by bacterial agents and is not increased in other types of inflammation, such as viral and autoimmune. Plasma values are very low in normal cases and are about 10 to 50 pg/ml [10, 11]. It can be used for the early detection of infections and also to monitor the response to a treatment [12]. Finally, gold standard for the identification of infections and bacteremia is microbial cultures, which also has some problems, for example, distinguishing between true bacteremia and contamination, polymicrobial cultures, and the timing of this method [13].

Selecting patients' with true bacteremia to initiate appropriate antibiotic therapy is important in controlling the mortality, especially in the oncology ward. Hence, we aimed to investigate the value of CRP and PCT to determine the value of each marker for early detection of true bacteremia for better management of these patients.

2. Methods and Materials

This study was performed on patients with clinical suspicion of infection in an oncology center in the city of Shiraz, Iran, in 2017-18. All of the patients with malignancy that had fever with a body core temperature of more than 37 degree were included in the study. If a patient was unwilling to cooperate or sample was unavailable, they were excluded from the study, and finally, 255 patients were included. Peripheral blood samples were taken before starting antibiotic treatment. One of the samples was sent for microbiological examination in BACTEC glass and the other in clot tube for evaluation of CRP and PCT markers. Another blood culture sample was taken from another site simultaneously. After taking cultures, empirical antibiotic therapy was started. Type of antibiotics was changed according to the results of antibiotic susceptibility testing. We did not change the antibiotics according the results of PCT/CRP. Antibiotic therapy was stopped 14 days after the first negative culture for Gram-positive bacteria and fungi. It was 21 days for Gram-negative bacteria. For a patient with negative culture, antibiotics were stopped 3 days after lowering the fever and stabilization of patient vital signs.

Demographic information, white blood cell count, and neutrophil count of patients were also recorded.

Peripheral blood BACTEC samples were analyzed by the BACTEC 9120 system. Positive samples were inoculated in 5% sheep blood agar, EMB agar, and chocolate agar and incubated for one day at 35–37°C. In case of microorganism growth, staining, colony morphology, biochemical tests, and automatic identification systems (API, bioMérieux, France) were used to identify the microorganism.

BACTEC samples were kept in the apparatus for up to 7 days if they did not grow. At the end of the seventh day, we considered microorganism growth as negative or non-bacteremia for cultures without organism growth (group I) and cultures with organism growth as bacteremia. In this group, bacteremia was divided into two groups: true bacteremia (group II) and contamination (group III). Identification of normal skin flora microorganisms, such as Staphylococcus aureus, Corynebacterium, and Streptococcus

viridans, in only one blood culture glass was considered as contamination. Coagulase-negative Staphylococci were considered to be true bacteremia, only when they are isolated in two blood cultures in two different times and with similar antibiotic susceptibility. Finally, we considered isolation of other microorganisms as true bacteremia. CRP levels were measured, using Bionik kit and BT 3000 autoanalyzer (based on latex immunoturbidometry). The PCT was measured on peripheral blood serum, using VIDAS product kit. Analytical sensitivity for PCT and CRP was 0.05 ng/ml and 0.05 mg/l, respectively.

Data were analyzed using SPSS version 9.1 and MedCalc version 8 software. One-way ANOVA statistical method was used to compare the mean of variables in different groups and the ROC curve to determine the value of PCT and CRP markers as well as sensitivity and specificity of different cutoffs. *P* values less than 0.05 were considered to be statistically significant. The local ethics committee of Shiraz University of Medical Sciences approved this study.

3. Results

Of the 255 investigated patients, 135 were male (52.9%) and 120 were female (47.1%). From the 255 patients, 234 were children (91.8%) and the rest were adults (8.2%). The mean age of the children was 7.3 ± 5.5 years, and the mean age of the adults was 36 ± 1.6 years.

In our study, we focused on all of the patients with malignancy and fever without any concentration on special type of malignancy. Most of the pediatric patients (164) had hematologic malignancy (70.08%) and also the same was true about the adult patients, hematologic malignancies (15, 71.42%). Detailed distribution of recruited patients are as follows: acute lymphoblastic leukemia (ALL), 97 (38.0%); acute myelogenous leukemia (AML), 62 (24.3%); non Hodgkin lymphoma (NHL), 17 (6.7%); Hodgkin lymphoma (HL), 1 (0.4%); neuroblastoma, 9 (3.5%); Wilms' tumor, 7 (2.7%); hepatoblastoma, 9 (2.7%); germ cell tumor, 8 (3.5%); PNET/Ewing's sarcoma, 20 (7.8%); rhabdomyosarcoma, 5 (2.0%); brain tumor, 10 (3.9%); lung adenocarcinoma, 1 (0.4%); colorectal cancer, 3 (1.2%); multiple myeloma (MM), 2 (0.8%); osteosarcoma, 3 (1.2%); and pleuropulmonary blastoma, 1 (0.4%).

From our patients, 88 of them (34.51%) had neutropenia with less than 500 neutrophils per microliter by definition. It is named febrile neutropenia.

Blood culture was considered as the gold standard for the diagnosis of bacteremia. The most abundant microorganism species in the bacteremia group were as follows: *E. coli*, coagulase-negative *Staphylococcus*, and non-albicans *Candida*, with three cases of each, and the rest one case *Enterococcus*, Group A *Streptococci*, group D hemolytic *Streptococcus*, *Salmonella*, *Pseudomonas*, and *Candida albicans*. In the contamination group, in three patients, *Streptococcus viridans* organism and in one patient, *Micrococcus* organism were detected. Based on the criteria and clinic of these patients, they were grouped as contaminated.

The lowest and highest and mean of WBC levels in the bacterial and nonbacterial groups and the contamination are

TABLE 1: Lowest and highest WBC averages across groups.

WBC/mm ³	Lowest	Highest	Mean
Nonbacteremia	30	77700	6059
Bacteremia	60	25000	5930
Contamination	2700	8500	6500
Gram-positive	200	25000	9800
Gram-negative	60	13900	3512
Fungal	140	7700	3150

TABLE 2: The lowest and highest and mean of CRP and PCT concentrations.

Result	Count	CRP mean (lowest-highest)	ANOVA ($P < 0.274$)	PCT mean (lowest-highest)	
Nonbacteremia (group I)	236	62.27 (2–211)		1.47 (0.27–47)	
Bacteremia (group II)	15	76.6 (18–141)	>0.05	13.93 (0.12–100)	
Gram-positive (G+)	6	84.77 (29–121)	>0.05	1.7 (0.22–4.32)	
Gram-negative (G–)	5	62.4 (18–108)	>0.05	28.7 (0.2–100)	
Fungal (F)	4	82.25 (56–141)	>0.05	13.7 (0.12–52.09)	
Contamination (group III)	4	42.50 (6–99)	>0.05	1.10 (0.1–3.9)	
<i>P</i> value for PCT between groups					
I vs. II	II vs. III	I vs. III	G– vs. G+	G– vs. F	G+ vs. F
0.000	0.013	0.995	0.000	0.028	0.096

shown in Table 1. There was no significant difference between groups in WBC values (P value >0.05).

According to clinical conditions, there was a statistical significant difference in PCT concentration between the bacteremia group and nonbacteremia as well as the contamination group. Also, there was a statistical significant difference in the PCT level between Gram-negative group and Gram-positive as well as fungal group. There was no statistical difference in the CRP level between these abovementioned groups (Table 2).

The ROC curve was used to compare the value of these two markers to distinguish bacteremia from nonbacteremia and also bacteremia from contamination (Table 3). Only PCT and combination of PCT and CRP were statistically significant in distinguishing bacteremia from nonbacteremia patients. However, significant difference was not seen between the AUC values of PCT and those of CRP (P value: 0.183). Figure 1 displays the ROC curves of the PCT and CRP for discriminating bacteremia from other groups. We also compared the sensitivity of both markers in these two groups at fixed specificities of 50%, 75%, and 98% (Table 4). As shown, the sensitivities of PCT at different specificities are higher than CRP.

Using ROC curve results, the new CRP cutoff and PCT cutoff to distinguish bacteremia from nonbacteremia was 47 mg/dl and 1.17 ng/ml, respectively, with sensitivity, specificity, PPV, and NPV that are shown in Table 5.

4. Discussion

In infections, CRP and PCT are used as diagnostic markers. Due to the importance of rapid diagnosis of sepsis in immunosuppressed oncology patients, it is imperative to find a marker that can quickly and accurately predict the

TABLE 3: PCT and CRP area under ROC curve value between bacteremia and nonbacteremia groups.

Groups	Parameter	AUC	95% CI	<i>P</i> value
<i>Bacteremia vs. nonbacteremia</i>	CRP	0.612	0.549–0.673	0.1463
	PCT	0.741	0.682–0.794	0.0015
	Combined PCT and CRP	0.693	0.632 to 0.749	0.0058
<i>Bacteremia vs. contamination</i>	CRP	0.758	0.921–0.511	0.8167
	PCT	0.783	0.538–0.935	0.8625

probability of sepsis and bacteremia. In this study, we evaluated the value of CRP marker and PCT in differentiating bacteremia from nonbacteremia as well as differentiating bacteremia from contamination in peripheral blood cultures. The results showed that the mean value of the PCT level was significantly higher in the bacteremia than the nonbacteremia group, and this value was also significantly higher in the bacteremia than the contamination group. However, there was no significant difference in CRP values between these bacterial and nonbacterial as well as contamination groups. Also, in comparison between bacteremia and nonbacteremia, the AUC of PCT was higher than CRP, and the P value of PCT as a single test was statistically significant, but it is not for CRP. In fixed specificities, the sensitivities of PCT were higher than CRP in bacteremia versus nonbacteremia groups. All of these findings are in favor of a greater value of PCT to distinguish bacteremia from nonbacteremia, which might be due to increased production of CRP in cancer, especially hematologic malignancies [14]. Similar to our findings, several other studies also reported the same thing on oncology patients [14–20]. In a number of studies in contrast to ours and previous




FIGURE 1: ROC curve of PCT and CRP in diagnosing bloodstream infections in oncology patients (a) between bacteremia and non-bacteremia groups, (b) between bacteremia and contamination groups, and (c) combined PCT and CRP between bacteremia and non-bacteremia groups.

studies, it is stated that there is no statistical difference between PCT values in comparison with CRP [21–24]. It may be due to the use of old assay methods with poor analytical sensitivities.

In our study, the difference in PCT averages in Gram-negative bacteremia in comparison with Gram-positive as well as fungal groups was statistically significant, which was confirmed by most of the previous studies [14–20]. In contrast, in few studies, this difference of PCT in Gram-negative bacteremia was not statistically significant [23, 24]. Between these groups, CRP was not statistically significant.

According to ROC analysis for PCT, at the optimal cutoff value of 1.17 ng/ml (bacteremia from nonbacteremia) in

comparison with a standard cutoff value of 0.5, the NPV value was 97.46% with a higher specificity of 80.08% in malignant patients, suspicious of sepsis. With this higher cutoff value, with more certainty, we can exclude blood infections in oncology patients.

In this study, we found few cases with a significant increase in PCT levels, which had negative peripheral blood cultures. In clinical studies, other causes such as urosepsis and involvement with invading fungi such as *Aspergillus* might attribute to elevated levels of this marker in the absence of bacteremia. However, given the context of immunosuppression amongst our patients and the possibility of respiratory and urinary infection as well as the effect of

TABLE 4: Sensitivity and cutoff level of PCT and CRP at fixed specificities between bacteremia and nonbacteremia groups.

Marker		Specificity		
		50	75	98
PCT	Cutoff (ng/ml)	0.36	0.899	13
	Sensitivity %	73.33	66.67	20
CRP	Cutoff (ng/ml)	61	84	126
	Sensitivity %	66.67	40	6.67

TABLE 5: Sensitivity and specificity and PPV and NPV of CRP and PCT markers to distinguish bacteremia from nonbacteremia at optimal cutoff in comparison with standard cutoff based on ROC curve results.

Marker		Cutoff	Sensitivity (95% CI) in %	Specificity (95% CI) in %	PPV in %	NPV in %
PCT	Standard cutoff (ng/ml)	0.5	73.33 (44.9–92.2)	61.86 (55.3–68.1)	10.76	97.37
	Optimal cutoff (ng/ml)	1.17	66.67 (38.4–88.2)	80.08 (74.4–85)	17.34	97.46
CRP	Standard cutoff (mg/l)	10	100 (78.2–100)	7.63 (4.6–11.8)	6.36	100
	Optimal cutoff (mg/l)	47	86.67 (59.5–98.3)	33.05 (27.1–39.4)	7.5	97.53

chemotherapy drugs, these two inflammatory markers can be elevated without the presence of clear bacteremia. In addition, transient bacteremia and inappropriate timing might be the other causes of these inconsistencies between high levels of CRP and PCT with peripheral blood cultures.

One significant limitation of our study was very low number of contamination group cases which our suggestion is a study with more number of contaminated cases before and after good training of personnel.

In conclusion, according to recent study, there was a significant difference between the mean of PCT in the bacteremia and nonbacteremia group, and lack of this difference for CRP showed that PCT was better in differentiating bacteremia from nonbacteremia and also in Gram-negative cases versus other positive cultures in patients with malignancy.

Data Availability

The data supporting the findings of this study are available within the article.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors wish to thank Shiraz University of Medical Sciences, Shiraz, Iran, and also Center for Development of Clinical Research of Namazee Hospital, Ms. Sh. Milady for statistical assistance, and Mr. H. Argasi, Research Consultation Center (RCC) of Shiraz University of Medical Sciences, for assistance in editing this manuscript.

References

- [1] N. M. Kuderer, D. C. Dale, J. Crawford, L. E. Cosler, and G. H. Lyman, "Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients," *Cancer*, vol. 106, no. 10, pp. 2258–2266, 2006.
- [2] G. H. Lyman, N. M. Kuderer, J. Crawford et al., "Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy," *Cancer*, vol. 117, no. 9, pp. 1917–1927, 2011.
- [3] G.P. Bodey, R. V. Victorio, H. Y. Chang et al., "Fever and infection in leukemic patients. A study of 494 consecutive patients," *Cancer*, vol. 41, no. 4, pp. 1610–1622, 1978.
- [4] M. J. Arbo, M. J. Fine, B. H. Hanusa, T. Sefcik, and W. N. Kapoor, "Fever of nosocomial origin: etiology, risk factors, and outcomes," *The American Journal of Medicine*, vol. 95, no. 5, pp. 505–512, 1993.
- [5] F. Adnet, S. W. Borron, E. Vicaut et al., "Value of C-reactive protein in the detection of bacterial contamination at the time of presentation in drug-induced aspiration pneumonia," *Chest*, vol. 112, no. 2, pp. 466–471, 1997.
- [6] S. Z. Saeedinejad, M. Shirvani, and N. Omidifar, "Survey of relationship between changes in serum levels of procalcitonin with response to treatment in patients with SIRS positive Acute pyelonephritis," *World Family Medicine Journal/ Middle East Journal of Family Medicine*, vol. 15, no. 10, pp. 198–201, 2017.
- [7] W. S. Tillett and T. Francis, "Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus," *Journal of Experimental Medicine*, vol. 52, no. 4, pp. 561–571, 1930.
- [8] C. Gabay and I. Kushner, "Acute-phase proteins and other systemic responses to inflammation," *New England Journal of Medicine*, vol. 340, no. 6, pp. 448–454, 1999.
- [9] E. Suprin, C. Camus, A. Gacouin et al., "Procalcitonin: a valuable indicator of infection in a medical ICU?" *Intensive Care Medicine*, vol. 26, no. 9, pp. 1232–1238, 2000.
- [10] M. Assicot, C. Bohuon, D. Gendrel, J. Raymond, H. Carsin, and J. Guilbaud, "High serum procalcitonin concentrations in patients with sepsis and infection," *The Lancet*, vol. 341, no. 8844, pp. 515–518, 1993.
- [11] S. Russwurm, I. Stonāns, E. Stonāne et al., "Procalcitonin and CGRP-I mRNA expression in various human tissues," *Shock*, vol. 16, no. 2, pp. 109–112, 2001.
- [12] H. Ugarte, E. Silva, D. Mercan, A. De Mendonca, and J.-L. Vincent, "Procalcitonin used as a marker of infection in the intensive care unit," *Critical Care Medicine*, vol. 27, no. 3, pp. 498–504, 1999.

- [13] J. Cohen, C. Brun-Buisson, A. Torres et al., "Diagnosis of infection in sepsis: an evidence-based review," *Critical Care Medicine*, vol. 32, no. 11, pp. S466–S494, 2004.
- [14] F. Li, W. Zhang, H. Hu, Y. Zhang, and D. Huang, "Diagnostic value of procalcitonin, C-reactive protein and lactate dehydrogenase in paediatric malignant solid tumour concurrent with infection and tumour progression," *Scientific Reports*, vol. 9, no. 1, p. 5903, 2019.
- [15] L. G. de Guadiana-Romualdo, I. Espanol-morales, P. Cerezuela-Fuentes et al., "Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6," *Supportive Care in Cancer*, vol. 23, no. 7, pp. 2175–2182, 2015.
- [16] I. Yunus, A. Fasih, and Y. Wang, "The use of procalcitonin in the determination of severity of sepsis, patient outcomes and infection characteristics," *PLoS One*, vol. 13, no. 11, Article ID e0206527, 2018.
- [17] S. Jeong, Y. Park, Y. Cho, and H. S. Kim, "Diagnostic utilities of procalcitonin and C-reactive protein for the prediction of bacteremia determined by blood culture," *Clinica Chimica Acta*, vol. 413, no. 21-22, pp. 1731–1736, 2012.
- [18] M. Plesko, J. Suvada, M. Makohusova et al., "The role of CRP, PCT, IL-6 and presepsin in early diagnosis of bacterial infectious complications in paediatric haemato-oncological patients," *Neoplasma*, vol. 63, no. 5, pp. 752–760, 2016.
- [19] S. R. Nath, S. Jayapalan, H. Nair et al., "Comparative diagnostic test evaluation of serum procalcitonin and C-reactive protein in suspected bloodstream infections in children with cancer," *Journal of Medical Microbiology*, vol. 66, no. 5, pp. 622–627, 2017.
- [20] X.-J. Xu, Z.-B. Luo, T. Xia et al., "Comparison of interleukin-6, interleukin-10, procalcitonin and C-reactive protein in identifying high-risk febrile illness in pediatric cancer patients: a prospective observational study," *Cytokine*, vol. 116, pp. 1–6, 2019.
- [21] T. Xia, X. Xu, N. Zhao, Z. Luo, and Y. Tang, "Comparison of the diagnostic power of cytokine patterns and procalcitonin for predicting infection among paediatric haematology/oncology patients," *Clinical Microbiology and Infection*, vol. 22, no. 12, pp. 996–1001, 2016.
- [22] A. Verlinden, V. De Vroey, H. Goossens et al., "Comparison of the power of procalcitonin and c-reactive protein to discriminate between different aetiologies of fever in prolonged profound neutropenia: a single-centre prospective observational study," *Mediterranean Journal of Hematology and Infectious Diseases*, vol. 11, no. 1, Article ID e2019023, 2019.
- [23] Z. Ş Bal, G. Ercan, and D. Y. Karapinar, "Can serial measurement enhance the diagnostic value of procalcitonin as a marker of gram-negative bacteremia in children with acute leukemia?" *The Journal of Pediatric Research*, vol. 6, no. 2, pp. 99–103, 2019.
- [24] T. Demirdal, P. Sen, and S. A. Nemli, "Diagnostic value of procalcitonin in predicting bacteremia in intensive care unit," *Indian Journal of Critical Care Medicine*, vol. 22, no. 2, pp. 78–84, 2018.